Key Highlights
- Certara (NASDAQ:CERT) trades in the lower half of a 52-week range of US$4.45 to US$13.88, according to aggregated market data.
- Certara last reported for the quarter ended; second-quarter figures were unpublished as.
- The bull case rests on mix. Software grew revenue 18% in 2025 and bookings 20% in the March quarter, and is the higher-margin half of the group; every quarter it expands while services contract shifts the base towards recurring income.
- First, services are deteriorating rather than lapping tough comparatives: revenue fell 4% and bookings 14% in the March quarter.
Why the market is paying attention
Certara (NASDAQ:CERT) trades in the lower half of a 52-week range of US$4.45 to US$13.88, according to aggregated market data. With 155.6m shares outstanding, that is a market capitalisation of about US$1.21bn.
The Nasdaq-listed biosimulation specialist is midway through its biggest reshaping since its 2020 listing. It sold its global medical writing and regulatory services division to Veristat, LLC, and the same week cut 2026 adjusted earnings guidance. Five weeks later its finance chief resigned.
The question is whether the software and AI business left behind can grow fast enough to offset a shrinking services arm.
What the company does
Certara sells biosimulation software and scientific services to drug developers. Biosimulation uses mathematical models of human biology to predict how a compound moves through the body and what dose will work, reducing the questions settled in physical experiments or patient trials.
Its products include the Simcyp Simulator for physiologically based pharmacokinetic modelling, the Phoenix analysis suite, Pinnacle 21 for clinical data standards, D360 for discovery informatics, Chemaxon's chemistry software, bought for US$96.4m in 2024, and Applied BioMath's systems pharmacology tools, acquired for US$36.6m in 2023.
The FY2025 annual report says Certara has worked with more than 2,600 life sciences companies and academic institutions, that its customers received 90% or more of all novel FDA drug approvals from 2014 to 2025, and that 20 drug regulatory agencies use its software.
Latest financial and operating performance
Certara last reported for the quarter ended; second-quarter figures were unpublished as. Revenue was US$106.9m, up about 1%: software rose 7% to US$49.7m, services fell 4% to US$57.2m. Cost of revenues of US$41.6m left a gross margin near 61%.
Operating expenses climbed to US$69.6m from US$56.9m, mainly on general and administrative costs of US$29.4m against US$19.7m, which included a US$7.2m contingent-consideration charge from past acquisitions. Certara swung to a US$4.3m operating loss from US$7.6m of income, and to a net loss of US$8.8m, or US$0.06 a share.
Adjusted EBITDA fell 9% to US$31.7m, a margin near 30%, and adjusted diluted EPS fell to US$0.09 from US$0.14. Bookings, the forward order metric, totalled US$115.3m, down 2%: software bookings jumped 20% to US$48.7m, services fell 14% to US$66.6m.
For 2025 as a whole revenue was US$418.8m, up 9%, software up 18% and services up 3%; adjusted EBITDA was US$134.5m, a 32% margin, and the net loss narrowed to US$1.6m.
Cash stood at US$149.5m on 31 March, down from US$189.4m after US$40m of buybacks, against term debt of about US$292.5m and an undrawn US$100m revolver. Operating cash flow was US$11.7m. Guidance for 2026, cut in May and reaffirmed on 17 June, is revenue of US$395m to US$405m, an adjusted EBITDA margin of 30% to 32% and adjusted EPS of US$0.35 to US$0.41.
The catalyst: selling the services, keeping the software
The Veristat deal is the clearest signal of intent. Certara sold the division for US$85m cash plus US$15m escrow, with up to US$35m of earn-out, and expects a loss of roughly US$28.9m to US$53.7m: the assets were carried well above what a buyer would pay.
Medical writing is a headcount business with little operating leverage; software is not. Removing about US$18m of slow-growing revenue tilts the group towards the half where March-quarter bookings grew 20%.
In its place comes artificial intelligence. Chief executive Jon Resnick, in post, framed the strategy as divesting medical writing, reorganising around two focused growth areas and accelerating an enterprise-wide AI programme. Certara markets Certara.AI, purpose-built GPT models trained on biomedical data, and CoAuthor, a generative-AI regulatory-writing product, so it has sold the human writing service while keeping the software meant to automate it.
The bull case
The bull case rests on mix. Software grew revenue 18% in 2025 and bookings 20% in the March quarter, and is the higher-margin half of the group; every quarter it expands while services contract shifts the base towards recurring income.
Regulatory entrenchment is hard to replicate: Certara's models are used by 20 regulatory agencies and its customers sat behind most novel FDA approvals of the past decade, unusual for a company trading near 2.9 times trailing revenue.
Leverage is modest. Net debt of about US$143m is roughly one times 2025 adjusted EBITDA, before the US$85m received from Veristat.
The bear case and the risks
First, services are deteriorating rather than lapping tough comparatives: revenue fell 4% and bookings 14% in the March quarter. The then finance chief blamed execution and go-to-market problems he expected to fix in the second half, a plan, not a result.
Second, the balance sheet is overwhelmingly intangible: goodwill of US$770.8m and other intangibles of US$433.3m are about 80% of US$1.50bn of total assets and exceed equity of US$1.02bn. Certara wrote off US$47.0m of goodwill in 2023; a sustained share-price fall could force another test.
Third, guidance has already been cut once: February's 2026 adjusted EPS range of US$0.44 to US$0.48 became US$0.35 to US$0.41 by May. Fourth, the finance function is unsettled: John Gallagher resigned as chief financial officer and treasurer Faiz Mohammed took the role on an interim basis from 15 July.
Fifth, demand depends on customers' access to capital: Certara's risk disclosures cite a pulling back of government support and funding for drug development, and warn that smaller biotech customers are less financially secure and may not pay if they cannot raise capital.
What investors should watch next
Second-quarter results. Certara had not reported for the June quarter as. It is the first test of promised second-half services execution and the first period shaped by the Veristat sale.
Services bookings. A return to growth after a 14% decline would support the executional diagnosis; further double-digit falls would suggest something structural.
The disposal loss and guidance. The loss is estimated only within a US$28.9m to US$53.7m band, subject to working-capital and earn-out outcomes. The reaffirmed US$395m to US$405m revenue and US$0.35 to US$0.41 EPS ranges are the other test, alongside the naming of a permanent finance chief.
Investor takeaway
Certara is a differentiated asset in an awkward transition. The biosimulation software franchise is embedded with regulators and grew bookings 20% in the March quarter, and selling a lower-margin services division at a loss suggests management will shrink the group to improve its shape.
Against that, it is loss-making on a reported basis, cut its earnings guidance within three months of issuing it, carries more than US$1.2bn of goodwill and intangibles against a US$1.21bn market capitalisation, and is running with an interim finance chief. The second-quarter report should show whether services stabilised and how the AI products are selling. Until then the case rests on a turnaround described but not yet demonstrated.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.

_11_16_2026_14_11_57_237005.jpg)




Please wait processing your request...